(S)-(+)-Ibuprofen
Based on 1 Customer Validation
(S)-(+)-Ibuprofen ((S)-Ibuprofen), a S(+)-enantiomer of Ibuprofen, is a potent COX-1 and COX-2 inhibitor with IC50s of 2.1 μM and 1.6 μM, respectively. (S)-(+)-Ibuprofen has analgesic, anti-inflammatory, anticancer and antipyretic effects.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.95%
- CAS No.: 51146-56-6
- 화학식: C13H18O2
- 분자량:206.28
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Immunology/Inflammation Compound Library
HY-L007
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Pyroptosis Compound Library
HY-L059
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Antidepressant Compound Library
HY-L108
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Off-patent Drug Library
HY-L141
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
Biological Activity
|
COX-1 2.1 μM (IC50) |
COX-2 1.6 μM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEL | IC50 |
98.65 nM
Compound: Ibuprofen
|
Inhibition of COX1 in human HEL 92.1.7 cells assessed as thromboxane B2 production incubated for 30 mins before arachidonic acid addition measured after 15 mins by ELISA
Inhibition of COX1 in human HEL 92.1.7 cells assessed as thromboxane B2 production incubated for 30 mins before arachidonic acid addition measured after 15 mins by ELISA
|
[PMID: 21602044] |
| HT-29 | IC50 |
>1000 μM
Compound: dexibuprofen
|
Antiproliferative activity against HT29 cells
Antiproliferative activity against HT29 cells
|
[PMID: 17110105] |
| MCF7 | IC50 |
795 μM
Compound: dexibuprofen
|
Antiproliferative activity against MCF7 cells
Antiproliferative activity against MCF7 cells
|
[PMID: 17110105] |
| U-937 | IC50 |
0.73 μM
Compound: Ibuprofen
|
Inhibition of COX2 in LPS-stimulated and PMA-treated human U937 cells assessed as PGE2 production after 15 mins by ELISA
Inhibition of COX2 in LPS-stimulated and PMA-treated human U937 cells assessed as PGE2 production after 15 mins by ELISA
|
[PMID: 21602044] |
(S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 0-1000 μM; 8 days) treatment reduces concentration dependently cell survival in both cell lines to a similar extent[2].
(S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 0-1000 μM; 20-72 hours) treatment causes a G0/G1 phase block as well as apoptosis[2].
(S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 900 μM; 4-72 hours) treatment shows a down regulation of cyclin A and B and an increase of the cell cycle inhibitory protein p27Kip-1[2].
(S)-(+)-Ibuprofen inhibits COX activity, thromboxane formation, and platelet aggregation[1].
(S)-(+)-Ibuprofen inhibits the activation of NF-κB in response to T-cell stimulation with an IC50 of 61.7 μM[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HCT-15 and HCA-7 cells
-
Concentration:0 µM, 200 µM, 400 µM, 600 µM, 700 µM, 800 µM, 900 µM, and 1000 µM
-
Incubation Time:8 days
-
Result:Reduced concentration dependently cell survival in both cell lines to a similar extent.
-
Cell Line:HCT-15 and HCA-7 cells
-
Concentration:0 µM, 200 µM, 400 µM, 600 µM, 800 µM, 900 µM, and 1000 µM
-
Incubation Time:24 hours (HCT-15) or 20 hours (HCA-7)
-
Result:Caused a G0/G1 phase block.
-
Cell Line:HCT-15 and HCA-7 cells
-
Concentration:0 µM, 200 µM, 400 µM, 600 µM, 800 µM, 900 µM, and 1000 µM
-
Incubation Time:72 hours
-
Result:Induced cell apoptosis.
-
Cell Line:HCT-15 and HCA-7 cells
-
Concentration:900 µM
-
Incubation Time:4 hours, 8 hours, 16 hours, 24 hours, 32 hours, 48 hours and 72 hours
-
Result:Decreased levels of Cyclin D1 protein.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NMRI (nu/nu) male mice (6-8 week old ) injected with HCA-7 and HCT-15 cells[2]
-
Dosage:15 mg/kg/day
-
Administration:Intraperitoneal injection; five days a week; for 4 weeks
-
Result:Inhibited tumor growth of HCA-7 and HCT-15 xenografts in mice.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 51146-56-6
-
Appearance Solid
-
분자량 206.28
-
화학식 C13H18O2
-
Color White to off-white
-
SMILES
OC([C@H](C1=CC=C(CC(C)C)C=C1)C)=O
-
Synonyms
Dexibuprofen
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
용액&용해도
DMSO : 100 mg/mL (484.78 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 100 mg/mL (484.78 mM; Need ultrasonic)
H2O : 1 mg/mL (4.85 mM; Need ultrasonic and warming)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (12.12 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (12.12 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (12.12 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (12.12 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 6.67 mg/mL (32.33 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Evans AM, et al. Comparative pharmacology of S(+)-ibuprofen and (RS)-ibuprofen. Clin Rheumatol. 2001 Nov;20 Suppl 1:S9-14. [Content Brief]
[2]. Astrid Janssen, et al. Evidence of COX-2 independent induction of apoptosis and cell cycle block in human colon carcinoma cells after S- or R-ibuprofen treatment. Eur J Pharmacol. 2006 Jul 1;540(1-3):24-33. [Content Brief]
[3]. N Scheuren, et al. Modulation of transcription factor NF-kappaB by enantiomers of the nonsteroidal drug ibuprofen. Br J Pharmacol. 1998 Feb;123(4):645-52. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO / Ethanol | 1 mM | 4.8478 mL | 24.2389 mL | 48.4778 mL | 121.1945 mL |
| DMSO / Ethanol | 5 mM | 0.9696 mL | 4.8478 mL | 9.6956 mL | 24.2389 mL |
| 10 mM | 0.4848 mL | 2.4239 mL | 4.8478 mL | 12.1194 mL | |
| 15 mM | 0.3232 mL | 1.6159 mL | 3.2319 mL | 8.0796 mL | |
| 20 mM | 0.2424 mL | 1.2119 mL | 2.4239 mL | 6.0597 mL | |
| 25 mM | 0.1939 mL | 0.9696 mL | 1.9391 mL | 4.8478 mL | |
| 30 mM | 0.1616 mL | 0.8080 mL | 1.6159 mL | 4.0398 mL | |
| 40 mM | 0.1212 mL | 0.6060 mL | 1.2119 mL | 3.0299 mL | |
| 50 mM | 0.0970 mL | 0.4848 mL | 0.9696 mL | 2.4239 mL | |
| 60 mM | 0.0808 mL | 0.4040 mL | 0.8080 mL | 2.0199 mL | |
| 80 mM | 0.0606 mL | 0.3030 mL | 0.6060 mL | 1.5149 mL | |
| 100 mM | 0.0485 mL | 0.2424 mL | 0.4848 mL | 1.2119 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
(S)-(+)-Ibuprofen Related Classifications
HY-78131A Related Classifications
Powered by Bioz